MDWD: VALUE phase III advances, NexoBrid hits record U.S. sales, 2026 revenue guidance reaffirmed
MediWound (MDWD) reported Q2 2026 progress in its EscharEx VALUE phase III trial and record U.S. sales for NexoBrid. The company said full-year revenue guidance of $24–$26 million was reaffirmed, while revenue fell year over year due to BARDA contract timing, with growth expected in H2 from government contracts and new programs.
How this was made
The 30-second read
Why it matters
For traders, the key actionable element is the reaffirmed 2026 revenue guidance ($24–$26M) alongside an explanation for YoY revenue weakness (government contract timing). Without new clinical endpoints or contract awards, the update is more expectation-management than a fresh catalyst.
Market read
Guidance reaffirmation with trial progress can stabilize sentiment, but the lack of new endpoints or contract specifics limits immediate re-rating potential.
What to watch
The article does not provide trial efficacy/safety details or specific BARDA program updates, so traders may need additional primary sources to judge whether VALUE progress translates into revenue acceleration.
Background
The piece summarizes a Q2 2026 update for MediWound, citing progress in its VALUE phase III trial and record NexoBrid US sales, while noting YoY revenue decline due to BARDA timing.
Ticker impact
MediWound says Q2 VALUE phase III progressed and reaffirmed full-year revenue guidance of $24–$26 million despite YoY decline from BARDA timing.
Likely modest support for the stock on guidance reaffirmation, with limited upside until BARDA-related revenue timing becomes clearer.
The article provides specific guidance ($24–$26M) and links YoY revenue decline to timing, which can affect near-term expectations but is not a new contract award or clinical readout.
Market effects
Adds incremental datapoints for biotech clinical development and government-contract revenue timing risk, but no broader sector catalyst is disclosed.
No regional market linkage beyond the company’s US government contracting context.
Limited global relevance; story is company-specific and tied to US BARDA timing.
Counterpoint
The guidance reaffirmation may be less informative if BARDA timing delays are structural, meaning the market may discount the range until contract milestones are confirmed.
Key entities
- companyMediWound Ltd.
Subject of the update, reporting VALUE phase III progress and reaffirming 2026 revenue guidance.
- clinical_programEscharEx (VALUE phase III)
Referenced as progressing in Q2 2026 within the VALUE phase III trial.
- productNexoBrid
Referenced for record US sales in Q2 2026.
- government_agencyBARDA
Cited as the reason for YoY revenue decline due to timing of government contracts.
